# Using Cannabinoids to Protect the Brain from Oxidative Stress > A government-owned patent describing how certain non-psychoactive cannabinoids can act as antioxidants to protect brain cells from damage caused by strokes, trauma, or diseases like Alzheimer's. - **Patent:** US 6630507 - **Original title:** Cannabinoids as antioxidants and neuroprotectants - **Owner:** US Department of Health and Human Services - **Granted:** 2003 - **Status:** Public domain (expired) - **Times cited:** 78 - **Field:** biotech, pharmaceutical ## What it does This patent claims a method for treating diseases caused by oxidative stress—where unstable molecules damage cells—by using specific cannabinoids that do not bind to the NMDA receptor. Unlike traditional cannabinoids that cause a 'high,' the patent focuses on compounds like cannabidiol (CBD) that act as antioxidants to prevent neurological damage. The mechanism involves protecting the central nervous system during ischemic events, such as a stroke, or chronic conditions like Parkinson's disease. By avoiding NMDA receptor interaction, the method aims to provide neuroprotection without the psychoactive side effects or toxicity associated with other cannabis-derived compounds. ## What it does NOT cover - Does not cover cannabinoids that act as antagonists at the NMDA receptor. - Does not cover treatments for conditions unrelated to oxidative stress or neurodegeneration. - Does not claim the discovery of the cannabis plant itself, but rather a specific medical application of purified cannabinoid compounds. - Does not cover psychoactive cannabinoids when used in a way that relies on their psychoactive properties. ## The clever bit The inventors identified that cannabinoids possess antioxidant properties independent of their well-known psychoactive effects, effectively decoupling the therapeutic benefit from the 'high' by targeting specific receptor profiles. ## Real-world examples 1. Epidiolex (a pharmaceutical-grade CBD) 2. Research into CBD for stroke recovery 3. Studies on neuroprotective agents for Alzheimer's disease ## Why it matters This patent is significant because it was held by the U.S. government, highlighting early federal interest in the therapeutic, non-recreational potential of cannabinoids. It provided a scientific foundation for investigating CBD as a neuroprotectant, moving the conversation beyond the recreational use of THC. It remains a frequently cited document in the ongoing debate and research regarding the medical legalization and pharmaceutical development of cannabis-derived drugs. ## Frequently asked questions ### What does Using Cannabinoids to Protect the Brain from Oxidative Stress cover? A government-owned patent describing how certain non-psychoactive cannabinoids can act as antioxidants to protect brain cells from damage caused by strokes, trauma, or diseases like Alzheimer's. ### Who owns patent US 6630507? US Department of Health and Human Services owns this patent, granted in 2003. ### When does this patent expire? This patent has expired and is now in the public domain — anyone can use the invention freely. ### What is patent US 6630507 cited by? This patent has been cited by 78 later patents that build on its ideas. ### What problem does this patent solve? This patent is significant because it was held by the U.S. government, highlighting early federal interest in the therapeutic, non-recreational potential of cannabinoids. It provided a scientific foundation for investigating CBD as a neuroprotectant, moving the conversation beyond the recreational use of THC. It remains a frequently cited document in the ongoing debate and research regarding the medical legalization and pharmaceutical development of cannabis-derived drugs. ### What does this patent NOT cover? Does not cover cannabinoids that act as antagonists at the NMDA receptor. **Full plain-English explainer:** https://patentbrief.org/patent/us/6630507/cannabinoids-as-antioxidants-and-neuroprotectants **Original patent:** https://patents.google.com/patent/US6630507 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [Tiny Lipid Balls for Precise, Better-Absorbed Cannabinoid Medicine](https://patentbrief.org/patent/us/20220304938/lipid-nanoparticle-compositions-and-methods-as-carriers-of-cannabinoids-in-stand) — This patent describes a drug delivery system using tiny lipid nanoparticles to encapsulate cannabinoids, making them easier for the body to absorb and allowing for precise, smaller doses. - [Using Dimethyl Fumarate to Treat Multiple Sclerosis](https://patentbrief.org/patent/us/8399514/gilenya-fingolimod) — A patent detailing the specific daily dosage of 480mg of dimethyl fumarate for treating multiple sclerosis to protect nerve cells. - [Using Blood Markers to Diagnose Stroke and Tell Its Type](https://patentbrief.org/patent/us/10914745/biomarker-based-methods-for-aiding-the-diagnosis-of-stroke) — This patent describes a two-step method for diagnosing a stroke and then determining if it's an ischemic stroke or a transient ischemic attack (TIA) by measuring specific protein levels in a patient's blood. - [Chemical Compounds for Treating Hepatitis C Virus](https://patentbrief.org/patent/us/8822430/epclusa-sofosbuvir-velpatasvir) — A patent describing specific chemical structures designed to stop the Hepatitis C virus from replicating in humans. - [Using a Blood Marker to Predict Concussion Risk and Severity](https://patentbrief.org/patent/us/12085565/sntf-is-a-blood-biomarker-for-the-diagnosis-and-prognosis-of-sports-related-conc) — This patent describes a method to diagnose and predict long-term issues from mild traumatic brain injury, like concussions, by measuring a specific protein fragment called SNTF in a blood sample.